drugset / Trial / NCT07203846
Modulation of Gut MicroFLORA With Rifaximin to Reduce High Platelet Reactivity in Post-ACS Patients on Ticagrelor
Phase 4
Not yet recruiting
50 enrolled
Collegium Medicum w Bydgoszczy
Ministry of Science and Higher Education, Poland · collab
NaSingle-groupOpen-labelTreatment
Summary
The FLORA-ACS study aims to evaluate the relationship between dysbiosis and high platelet reactivity during treatment with ticagrelor in patients with a history of acute coronary syndromes and investigate the use of rifaximin to eliminate dysbiosis and thus provide effective antiplatelet treatment.
Timeline
- Start
- 2026-01-01
- Primary completion
- 2026-12-31
- Completion
- 2027-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Rifaximin | Other / unclassified | 400 mg | Oral |